Skip Nav Destination
Issues
1 October 2013
-
Cover Image
Cover Image
Metformin administration significantly inhibited the growth of SMMC7721 cell-derived tumor xenografts in nude mice. The cover shows hematoxylin and eosin staining of the tumor tissue from control mice. For details, see the article by Zheng and colleagues on page 5372 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
CCR Focus
Human Cancer Biology
Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer
Clémentine Le Magnen; Lukas Bubendorf; Cyrill A. Rentsch; Chantal Mengus; Joel Gsponer; Tobias Zellweger; Malte Rieken; George N. Thalmann; Marco G. Cecchini; Markus Germann; Alexander Bachmann; Stephen Wyler; Michael Heberer; Giulio C. Spagnoli
Cancer Therapy: Preclinical
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Brent N. Rexer; Ritwik Ghosh; Archana Narasanna; Mónica Valeria Estrada; Anindita Chakrabarty; Youngchul Song; Jeffrey A. Engelman; Carlos L. Arteaga
Author Choice
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System
Julia A. Beaver; John P. Gustin; Kyung H. Yi; Anandita Rajpurohit; Matthew Thomas; Samuel F. Gilbert; D. Marc Rosen; Ben Ho Park; Josh Lauring
Imaging, Diagnosis, Prognosis
MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
Wei Meng; Zhenqing Ye; Ri Cui; James Perry; Vaia Dedousi-Huebner; Alexander Huebner; Yao Wang; Bin Li; Stefano Volinia; Hiroshi Nakanishi; Taewan Kim; Sung-Suk Suh; Leona W. Ayers; Patrick Ross; Carlo M. Croce; Arnab Chakravarti; Victor X. Jin; Tim Lautenschlaeger
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
Esa Kähkönen; Ivan Jambor; Jukka Kemppainen; Kaisa Lehtiö; Tove J. Grönroos; Anna Kuisma; Pauliina Luoto; Henri J. Sipilä; Tuula Tolvanen; Kalle Alanen; Jonna Silén; Markku Kallajoki; Anne Roivainen; Niklaus Schäfer; Roger Schibli; Martina Dragic; Anass Johayem; Ray Valencia; Sandra Borkowski; Heikki Minn
Cancer Therapy: Clinical
Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
Ana M. Gonzalez-Angulo; Funda Meric-Bernstam; Sant Chawla; Gerald Falchook; David Hong; Argun Akcakanat; Huiqin Chen; Aung Naing; Siqing Fu; Jennifer Wheler; Stacy Moulder; Thorunn Helgason; Shaoyi Li; Ileana Elias; Neil Desai; Razelle Kurzrock
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang; Charlie Gourley; C. Bethan Powell; Hilda High; Ronnie Shapira-Frommer; Vincent Castonguay; Jacques De Greve; Tina Atkinson; Timothy A. Yap; Shahneen Sandhu; Susana Banerjee; Lee-May Chen; Michael L. Friedlander; Bella Kaufman; Amit M. Oza; Ursula Matulonis; Louise J. Barber; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; James Campbell; Lina Chen; Johann S. de Bono; Martin E. Gore; Christopher J. Lord; Alan Ashworth; Stan B. Kaye
First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
André T. Brunetto; Joo Ern Ang; Rohit Lal; David Olmos; L. Rhoda Molife; Rebecca Kristeleit; Ann Parker; Isabel Casamayor; Muyibat Olaleye; Anna Mais; Bernhard Hauns; Vera Strobel; Bernd Hentsch; Johann S. de Bono
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Ayca Gucalp; Sara Tolaney; Steven J. Isakoff; James N. Ingle; Minetta C. Liu; Lisa A. Carey; Kimberly Blackwell; Hope Rugo; Lisle Nabell; Andres Forero; Vered Stearns; Ashley S. Doane; Michael Danso; Mary Ellen Moynahan; Lamia F. Momen; Joseph M. Gonzalez; Arooj Akhtar; Dilip D. Giri; Sujata Patil; Kimberly N. Feigin; Clifford A. Hudis; Tiffany A. Traina; on behalf of the Translational Breast Cancer Research Consortium (TBCRC 011)
Predictive Biomarkers and Personalized Medicine
MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
Martin J. van den Bent; Lale Erdem-Eraslan; Ahmed Idbaih; Johan de Rooi; Paul H.C. Eilers; Wim G.M. Spliet; Wilfred F.A. den Dunnen; Cees Tijssen; Pieter Wesseling; Peter A.E. Sillevis Smitt; Johan M. Kros; Thierry Gorlia; Pim J. French
Author Choice
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda; Keith A. Baggerly; Ying Wang; Ya Zhang; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam; Vicente Valero; Brian D. Lehmann; Jennifer A. Pietenpol; Gabriel N. Hortobagyi; W. Fraser Symmans; Naoto T. Ueno
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.